Navigation Links
InteKrin Therapeutics Announces Appointment of Geoffrey M. Parker as Chief Business Officer
Date:7/13/2009

LOS ALTOS, Calif., July 13 /PRNewswire/ -- InteKrin Therapeutics Inc. announced today that Geoffrey M. Parker has joined InteKrin as Chief Business Officer. Most recently, Mr. Parker served as a Managing Director and Partner in the Investment Banking Division of Goldman, Sachs & Co. Over the past ten years, Mr. Parker led Goldman Sachs' West Region Healthcare Investment Banking practice during which time he advised many of the biotechnology industry's leading companies.

"We are very pleased to have such an eminent healthcare business professional join us," said Denny Lanfear, InteKrin Chief Executive. "The expertise, insights and depth of business experience Geoff brings are complementary to the InteKrin team's capabilities as world class drug developers and scientists."

"InteKrin is an exciting opportunity and INT131 presents significant promise for patient benefit," said Geoff. "INT131 has the potential to be a breakthrough product, and I am delighted to be part of the InteKrin team as we complete our Phase 2 work and plan to advance into Phase 3."

About INT131

INT131 is a next-generation insulin sensitizer currently in Phase 2b testing that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Treating and improving insulin sensitivity in diabetic patients by activating PPAR-gamma is an important therapeutic tool for physicians, providing powerful glucose control and durability of effect. As a SPPARM, INT131 selectively modulates PPAR-gamma, thereby enabling the separation of PPAR gamma anti-diabetic efficacy from the well recognized TZD side effects.

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.


'/>"/>
SOURCE InteKrin Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
2. InteKrin Therapeutics Announces $20 Million Series C Financing
3. InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
4. Prime Therapeutics Receives TIPPS Certification
5. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
6. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
7. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
8. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
9. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
10. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
11. Prime Therapeutics Announces URAC Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... ... 29, 2017 , ... A New York high tech innovator and a Canadian ... effectiveness of Artificial Intelligence (AI) in helping nudge men forward to be more proactive ... President of the Canadian Men’s Health Foundation (CMHF), whose mission is to inspire men ...
(Date:5/28/2017)... ... May 28, 2017 , ... Florida Pain ... announce that Sheldon K. Cho, MD, has joined its Winter Haven practice. ... concentrates on minimally invasive techniques to treat and manage many types of pain. ...
(Date:5/27/2017)... , ... May 27, 2017 , ... From May 21-23, ... Oticon. The three-day event was held at the Marriott Syracuse Downtown Hotel in Syracuse, ... hearing brand and network of independent hearing healthcare providers to help them stay ahead ...
(Date:5/26/2017)... ... May 26, 2017 , ... The Radiology ... to focus on current legislative activity and the latest regulatory concerns impacting RBMA ... Sunday, Sept. 10, and will continue through Monday, Sept. 11, at the Ritz-Carlton, ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... ever copper, antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. ... “We are thrilled to partner with Cupron® to provide customers with a game ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... -- Global Health Intelligence (GHI), the leading healthcare ... published its 2017 ranking of the Best-Equipped Hospitals in ... analysis from GHI,s hospitals database for Latin America , ... The GHI database covers 86% of the hospitals in ... points for each institution in key areas such as beds, ...
(Date:5/9/2017)...  Demonstrating its commitment to representing research- based ... Pharmaceutical Research and Manufacturers of America (PhRMA) today ... now have to meet new research and development ... join PhRMA. "By putting in place ... clear message that being a member of PhRMA ...
(Date:5/6/2017)... Texas , May 5, 2017   Provista , ... with more than 200,000 customers, today announced Jim Cunniff ... a wealth of executive and business experience to Provista, including ... compounding pharmacy in California . He assumed ... "Jim is a great fit for Provista," says ...
Breaking Medicine Technology: